Literature DB >> 21721918

Insulin dysfunction and allostatic load in bipolar disorder.

Elisa Brietzke1, Flávio Kapczinski, Rodrigo Grassi-Oliveira, Iria Grande, Eduard Vieta, Roger S McIntyre.   

Abstract

Bipolar disorder (BD) is associated with substantial morbidity, as well as premature mortality. Available evidence indicates that 'stress-sensitive' chronic medical disorders, such as cardiovascular disease, obesity and Type 2 diabetes mellitus, are critical mediators and/or moderators of BD. Changes in physiologic systems implicated in allostasis have been proposed to impact brain structures and neurocognition, as well as medical comorbidity in this population. For example, abnormalities in insulin physiology, for example, insulin resistance, hyperinsulinemia and central insulinopenia, are implicated as effectors of allostatic load in BD. Insulin's critical role in CNS physiological (e.g., neurotrophism and synaptic plasticity) and pathophysiological (e.g., neurocognitive deficits, pro-apoptosis and amyloid deposition) processes is amply documented. This article introduces the concept that insulin is a mediator of allostatic load in the BD and possibly a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21721918     DOI: 10.1586/ern.10.185

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  10 in total

1.  The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders.

Authors:  Rodrigo B Mansur; Gabriel R Fries; Alisson P Trevizol; Mehala Subramaniapillai; Julie Lovshin; Kangguang Lin; Maj Vinberg; Roger C Ho; Elisa Brietzke; Roger S McIntyre
Journal:  Eur Neuropsychopharmacol       Date:  2018-11-06       Impact factor: 4.600

2.  The thrifty psychiatric phenotype.

Authors:  C Garcia-Rizo; E Fernandez-Egea; M Bernardo; B Kirkpatrick
Journal:  Acta Psychiatr Scand       Date:  2014-07-07       Impact factor: 6.392

Review 3.  Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal.

Authors:  Rajat Sandhir; Smriti Gupta
Journal:  World J Diabetes       Date:  2015-09-25

Review 4.  Allostatic load but not medical burden predicts memory performance in late-life bipolar disorder.

Authors:  Sophie R Vaccarino; Tarek K Rajji; Ariel G Gildengers; Sarah E S Waters; Meryl A Butters; Mahesh Menon; Daniel M Blumberger; Aristotle N Voineskos; Dielle Miranda; Benoit H Mulsant
Journal:  Int J Geriatr Psychiatry       Date:  2017-12-13       Impact factor: 3.485

Review 5.  Obesity in bipolar disorder: an overview.

Authors:  Susan L McElroy; Paul E Keck
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

6.  Cardiometabolic Health in Bipolar Disorder.

Authors:  David E Kemp; Jinbo Fan
Journal:  Psychiatr Ann       Date:  2012-05-01

7.  Insulin resistance, diabetes mellitus, and brain structure in bipolar disorders.

Authors:  Tomas Hajek; Cynthia Calkin; Ryan Blagdon; Claire Slaney; Rudolf Uher; Martin Alda
Journal:  Neuropsychopharmacology       Date:  2014-06-19       Impact factor: 7.853

Review 8.  Stress, Inflammation, and Cellular Vulnerability during Early Stages of Affective Disorders: Biomarker Strategies and Opportunities for Prevention and Intervention.

Authors:  Adam J Walker; Yesul Kim; J Blair Price; Rajas P Kale; Jane A McGillivray; Michael Berk; Susannah J Tye
Journal:  Front Psychiatry       Date:  2014-04-09       Impact factor: 4.157

Review 9.  The Energy Metabolism Dysfunction in Psychiatric Disorders Postmortem Brains: Focus on Proteomic Evidence.

Authors:  Giuliana S Zuccoli; Verônica M Saia-Cereda; Juliana M Nascimento; Daniel Martins-de-Souza
Journal:  Front Neurosci       Date:  2017-09-07       Impact factor: 4.677

10.  Blood-brain barrier imaging as a potential biomarker for bipolar disorder progression.

Authors:  Lyna Kamintsky; Kathleen A Cairns; Ronel Veksler; Chris Bowen; Steven D Beyea; Alon Friedman; Cynthia Calkin
Journal:  Neuroimage Clin       Date:  2019-10-22       Impact factor: 4.881

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.